A manifest of our clinical trials

Primary Outcome: Day 90 mortality for pneumonia patients

Remap-Cap

MEGAROX

Trial Update: The Mega-ROX trial has now hit 25,000 enrolments worldwide with only 15,000 more to go

PLATIPUS

Trial Update: The Mega-ROX trial has now hit 25,000 enrolments worldwide with only 15,000 more to go

MEGAROX TRIAL

  • REMAP-CAP

    Trial news: REMAP-CAP has been announced as one of three finalists for the Federartie Medisch Specialisten Science and Innovation Prize 2023.

    REMAP-CAP TRIAL

  • MEGAROX

    Trial Update: The Mega-ROX trial has now hit 25,000 enrolments worldwide with only 15,000 more to go

    MEGAROX TRIAL

  • PLATIPUS

    PLATIPUS uses an adaptive platform design, running multiple “domains” concurrently

    PLATIPUS TRIAL

Primary outcome: Improving outcomes for babies born preterm

Primary outcome: Improving outcomes for babies born preterm

Primary outcome:
Improving outcomes for babies born preterm

PLATIPUS uses an adaptive platform design, running multiple “domains” concurrently

PLATIPUS TRIAL

Primary Outcome: Day 90 mortality for pneumonia patients

Trial news: REMAP-CAP has been announced as one of three finalists for the Federartie Medisch Specialisten Science and Innovation Prize 2023. More on this here.

Remap-Cap